Related Experiment Videos
[Azaspirodecanodiones in clinical psychiatry]
V Conde López1, M Martínez Roig
1Area de Psiquiatría de la Facultad de Medicina, Universidad de Valladolid, España.
Actas Luso-Espanolas De Neurologia, Psiquiatria Y Ciencias Afines
|July 1, 1992
Summary
Buspirone, a nonbenzodiazepine anxiolytic, offers therapeutic benefits for generalized anxiety disorder and other neuropsychiatric conditions. This review highlights its efficacy and potential in long-term treatment, including for elderly patients.
Area of Science:
- Pharmacology and Psychiatry
- Neuroscience
Context:
- Review of azaspirodecanodiones, including buspirone, gepirone, and ipsapirone.
- Buspirone is a novel nonbenzodiazepine anxiolytic targeting the serotonin 1A receptor subtype.
- Focus on clinical and therapeutic applications of these compounds.
Purpose:
- To provide an updated review of therapeutic studies on azaspirodecanodiones, particularly buspirone.
- To explore their efficacy in various neuropsychiatric disorders.
- To highlight buspirone's role in anxiety, depression, substance abuse, and related conditions.
Summary:
- Buspirone acts as a partial agonist in the serotonergic system, primarily indicated for generalized anxiety disorder.
- Evidence suggests its utility in treating panic disorder, obsessive-compulsive disorder, depression, and substance dependence.
- The review underscores buspirone's potential for anxious elderly patients and in long-term therapeutic strategies.
Impact:
- Offers a comprehensive overview of buspirone's therapeutic profile.
- Identifies potential applications beyond generalized anxiety disorder, including depression and alcoholism.
- Emphasizes buspirone's value in managing complex neuropsychiatric conditions and its suitability for long-term use.